Industry / Belgium

Solvay Seeks Critical Mass

May 2006 | Company Finance Alert

Printable version
Bookmark

Belgium pharmaceutical, plastics and chemicals group Solvay is seeking critical mass in its drugs division to ensure future prosperity, following the release of impressive Q106 financial

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles

Attractive Location For Pharmaceutical R&D And Manufacturing

Industry / Belgium BMI View: In BMI's Business Environment Ratings for Q211, Belgium scored 64.5 out of a total of 100 in BMI's, placing it fifth in the western Europe matrix. Although growth in medicine sales is low, the...

February 2011

Pharmaceutical R&D: An Area Of Government Focus

Industry / Belgium BMI View: While Belgium is not a major hub for research and development (R&D) compared with some of its European neighbours, we believe the country is establishing itself as a centre for biotechnology....

December 2010

Pharmacy Reimbursement Rates To Be Fixed

Industry / Belgium As of April 2010, pharmacists in Belgium receive a fixed reimbursement amount of EUR3.88 plus VAT for every pack of medicines sold. This new system replaces the old proportional reimbursement rate of 31%,...

May 2010

Omega Pharma Sells Aresus Stake To Focus On OTC Drug Market

Industry / Belgium Continuing with its aim of strengthening its core over-the-counter (OTC) medicines business, Belgium-based Omega Pharma has agreed to sell its remaining 24.0% stake in medical devices company Arseus...

November 2009

National Health Insurance Drug Expenditure Growth Declining

Industry / Belgium In response to recent press reports stating that Belgium's national health insurance scheme Inami would see a budget growth of approximately 10% in 2009, the agency has stated that it has taken steps...

September 2009